A clinical trial is ongoing to address the feasibility of HER2-DC1 i.t. plus anti-HER2 antibodies in the neoadjuvant setting for patients with HER2pos BC (ClinicalTrials.gov: NCT03387553). This evidence concerns the gene ERBB2 and breast cancer.